Cortes-Vicente, ElenaAlvarez-Velasco, RodrigoSegovia, SoniaParadas, CarmenCasasnovas, CarlosGuerrero-Sola, AntonioPardo, JulioRamos-Fransi, AlbaSevilla, TeresaLopez-de-Munain, AdolfoGomez, Maria TeresaJerico, IvonneGutierrez-Gutierrez, GerardoPelayo-Negro, Ana LaraMartin, Maria AsuncionMendoza, Maria DoloresMoris, GermanRojas-Garcia, RicardDiaz-Manera, JordiQuerol, LuisGallardo, EduardVelez, BeatrizAlberti, Maria AntoniaGalan, LuciíaGarcia-Sobrino, TaniaMartinez-Piñeiro, AliciaLozano-Veintimilla, AnaFernandez-Torron, RobertoCano-Abascal, AngelIlla, Isabel2023-02-082023-02-082020-02-18Cortés-Vicente E, Álvarez-Velasco R, Segovia S, Paradas C, Casasnovas C, Guerrero-Sola A, et al. Clinical and therapeutic features of myasthenia gravis in adults based on age at onset. Neurology. 2020 Mar 17;94(11):e1171-e1180.http://hdl.handle.net/10668/15126To describe the characteristics of patients with very-late-onset myasthenia gravis (MG). This observational cross-sectional multicenter study was based on information in the neurologist-driven Spanish Registry of Neuromuscular Diseases (NMD-ES). All patients were >18 years of age at onset of MG and onset occurred between 2000 and 2016 in all cases. Patients were classified into 3 age subgroups: early-onset MG (age at onset 18 years of age at onset of MG and onset occurred between 2000 and 2016 in all cases. Patients were classified into 3 age subgroups: early-onset MG (age at onset A total of 939 patients from 15 hospitals were included: 288 (30.7%) had early-onset MG, 227 (24.2%) late-onset MG, and 424 (45.2%) very-late-onset MG. The mean follow-up was 9.1 years (SD 4.3). Patients with late onset and very late onset were more frequently men (p Patients with MG are primarily ≥65 years of age with anti-AChR antibodies and no thymoma. Although patients with very-late-onset MG may present life-threatening events at onset, they achieve a good outcome with fewer immunosuppressants when diagnosed and treated properly.enAge of OnsetFemaleMaleMyasthenia GravisAdultAgedCross-Sectional StudiesHumansMiddle AgedTreatment Outcomeresearch article32071167Restricted AccessPacientesHospitalesTimomaVidaNeurólogosAnticuerposMiastenia GravisInmunosupresores10.1212/WNL.00000000000089031526-632XPMC7220233https://europepmc.org/articles/pmc7220233?pdf=renderhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7220233/pdf